<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article240</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/SOME" style="display:block; margin-bottom:10px;">SOME Original</a></li>
<h2><strong>SOME</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Screening for Occult Cancer in Unprovoked Venous Thromboembolism".The New England Journal of Medicine. 2015.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does a screening strategy for occult cancer including comprehensive computed tomography (CT) of the abdomen and pelvis lead to a clinically significant benefit in patients who had a first unprovoked venous thromboembolism?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
The prevalence of occult cancer in patients with a first unprovoked venous thromboembolism is low, and routine CT screening of the abdomen and pelvis does not provide a clinically significant benefit in detecting missed cancers or reducing cancer-related mortality.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
<hr/><br/>
<h2><strong>Guidelines for cancer screening in patients with unprovoked venous thromboembolism vary, with some recommending limited occult-cancer screening, while others suggest more extensive modalities.</strong></h2><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, open-label, randomized, controlled trial<br/>
N=854 patients with first unprovoked symptomatic venous thromboembolism<br/>
Limited occult-cancer screening group (n=431)<br/>
Limited occult-cancer screening plus CT group (n=423)<br/>
Enrollment: October 2008 to April 2014<br/>
Follow-up: 1 year<br/>
Intention-to-treat analysis<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: Patients with a new diagnosis of first unprovoked symptomatic venous thromboembolism.<br/>
Exclusion Criteria: Age &lt;18 years, inability to provide informed consent, allergy to contrast media, creatinine clearance &lt;60 ml/min, claustrophobia or agoraphobia, weight &gt;130 kg, ulcerative colitis, or glaucoma.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were assigned to undergo limited screening (history, physical examination, basic blood testing, chest radiography, and age- and sex-specific cancer screening) or limited screening plus CT of the abdomen and pelvis.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Confirmed cancer missed by the screening strategy and detected by the end of the 1-year follow-up period.<br/>
<br/>
Secondary Outcomes: Total number of occult cancers diagnosed, number of early cancers diagnosed, 1-year cancer-related mortality, 1-year overall mortality, time to cancer diagnosis, incidence of recurrent venous thromboembolism<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Open-label design may introduce bias. The screening did not include CT of the chest as many patients had undergone CT pulmonary angiography for diagnosis of pulmonary embolism.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Heart and Stroke Foundation of Canada<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
